To include your compound in the COVID-19 Resource Center, submit it here.

bluebird reports additional Phase II/III data for Lenti-D gene therapy in childhood CALD

In October, bluebird bio Inc. (NASDAQ:BLUE) reported additional data from 17 boys with cerebral adrenoleukodystrophy (CALD) in the Phase II/III Starbeam (ALD-102) trial showing that Lenti-D led

Read the full 276 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE